Overview

  • Product name
    Anti-VLDL Receptor antibody
    See all VLDL Receptor primary antibodies
  • Description
    Rabbit polyclonal to VLDL Receptor
  • Tested applications
    Suitable for: IHC-P, WB, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Rabbit
  • Immunogen

    Synthetic peptide within Human VLDL Receptor aa 491-518 (internal sequence) conjugated to Keyhole Limpet Haemocyanin (KLH). The exact sequence is proprietary.
    Database link: P98155

  • Positive control
    • 293 cell line lysate; Human skeletal muscle tissue; 293 cells.

Applications

Our Abpromise guarantee covers the use of ab175507 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/10 - 1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB 1/1000. Predicted molecular weight: 96 kDa.
Flow Cyt 1/10 - 1/50. ab171870-Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody.

Target

  • Function
    Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation.
  • Tissue specificity
    Abundant in heart and skeletal muscle; also ovary and kidney; not in liver.
  • Involvement in disease
    Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1) [MIM:224050]; also known as dysequilibrium syndrome (DES) or non-progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures.
  • Sequence similarities
    Contains 3 EGF-like domains.
    Contains 8 LDL-receptor class A domains.
    Contains 6 LDL-receptor class B repeats.
  • Post-translational
    modifications
    Ubiquitinated at Lys-839 by MYLIP leading to degradation.
  • Cellular localization
    Membrane. Membrane > clathrin-coated pit.
  • Information by UniProt
  • Database links
  • Alternative names
    • FLJ35024 antibody
    • Very low density lipoprotein receptor antibody
    • Very low-density lipoprotein receptor antibody
    • VLDL R antibody
    • VLDL receptor antibody
    • VLDL-R antibody
    • VLDLR antibody
    • VLDLR_HUMAN antibody
    • VLDLRCH antibody
    see all

Images

  • Anti-VLDL Receptor antibody (ab175507) at 1/1000 dilution + 293 cell line lysate at 35 µg

    Predicted band size : 96 kDa
  • Immunohistochemical analysis of formalin fixed, paraffin embedded Human skeletal muscle tissue labeling VLDL Receptor with ab155077 at 1/10 dilution, followed by peroxidase conjugation of the secondary antibody and DAB staining.

  • Flow cytometric analysis of 293 cells labeling VLDL Receptor with ab175507 at 1/10 dilution (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

References

ab175507 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab175507.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up